Bourne Lent Asset Management’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.5M | Hold |
31,133
| – | – | 6.43% | 5 |
|
|
2025
Q4 | $21.1M | Sell |
31,133
-271
| -0.9% | -$185K | 6.99% | 6 |
|
|
2025
Q3 | $20.1M | Sell |
31,404
-193
| -0.6% | -$117K | 7.13% | 6 |
|
|
2025
Q2 | $16.9M | Sell |
31,597
-205
| -0.6% | -$98K | 6.56% | 6 |
|
|
2025
Q1 | $13.4M | Sell |
31,802
-7,715
| -20% | -$3.35M | 5.73% | 6 |
|
|
2024
Q4 | $16.3M | Buy |
39,517
+695
| +2% | +$305K | 6.23% | 6 |
|
|
2024
Q3 | $19.6M | Buy |
38,822
+180
| +0.5% | +$87.4K | 7.44% | 5 |
|
|
2024
Q2 | $18.8M | Sell |
38,642
-212
| -0.5% | -$106K | 7.22% | 6 |
|
|
2024
Q1 | $21M | Sell |
38,854
-45
| -0.1% | -$24.6K | 8.46% | 4 |
|
|
2023
Q4 | $21.6M | Buy |
38,899
+5,003
| +15% | +$2.35M | 8.76% | 4 |
|
|
2023
Q3 | $14.8M | Sell |
33,896
-35,325
| -51% | -$17.6M | 6.53% | 6 |
|
|
2023
Q2 | $34.8M | Sell |
69,221
-890
| -1% | -$426K | 12.12% | 2 |
|
|
2023
Q1 | $35.1M | Sell |
70,111
-225
| -0.3% | -$108K | 13.26% | 1 |
|
|
2022
Q4 | $28.7M | Sell |
70,336
-3,050
| -4% | -$1.18M | 12.3% | 1 |
|
|
2022
Q3 | $23.9M | Sell |
73,386
-800
| -1% | -$294K | 10.4% | 2 |
|
|
2022
Q2 | $26M | Sell |
74,186
-950
| -1% | -$387K | 10.33% | 3 |
|
|
2022
Q1 | $41.1M | Sell |
75,136
-3,900
| -5% | -$2.05M | 12.87% | 1 |
|
|
2021
Q4 | $52M | Sell |
79,036
-719
| -0.9% | -$451K | 13.92% | 1 |
|
|
2021
Q3 | $49.6M | Sell |
79,755
-2,325
| -3% | -$1.56M | 14.24% | 2 |
|
|
2021
Q2 | $51.8M | Sell |
82,080
-1,825
| -2% | -$1.01M | 14.56% | 2 |
|
|
2021
Q1 | $41.1M | Sell |
83,905
-1,500
| -2% | -$752K | 13.1% | 2 |
|
|
2020
Q4 | $42.7M | Sell |
85,405
-2,597
| -3% | -$1.16M | 14.06% | 2 |
|
|
2020
Q3 | $34.6M | Sell |
88,002
-200
| -0.2% | -$73.9K | 13.28% | 2 |
|
|
2020
Q2 | $29.1M | Sell |
88,202
-1,920
| -2% | -$556K | 12.57% | 2 |
|
|
2020
Q1 | $21.8M | Sell |
90,122
-400
| -0.4% | -$104K | 11.71% | 3 |
|
|
2019
Q4 | $23.6M | Sell |
90,522
-660
| -0.7% | -$174K | 11.13% | 3 |
|
|
2019
Q3 | $24.8M | Sell |
91,182
-6,955
| -7% | -$1.94M | 11.89% | 3 |
|
|
2019
Q2 | $27M | Sell |
98,137
-1,695
| -2% | -$418K | 12.95% | 3 |
|
|
2019
Q1 | $22.3M | Sell |
99,832
-4,600
| -4% | -$950K | 11.06% | 3 |
|
|
2018
Q4 | $19.4M | Buy |
104,432
+95
| +0.1% | +$19.5K | 11.5% | 3 |
|
|
2018
Q3 | $26M | Sell |
104,337
-1,410
| -1% | -$342K | 12.42% | 3 |
|
|
2018
Q2 | $23M | Sell |
105,747
-5,040
| -5% | -$1.04M | 12.15% | 3 |
|
|
2018
Q1 | $21.2M | Sell |
110,787
-238
| -0.2% | -$43.9K | 11.52% | 3 |
|
|
2017
Q4 | $17.4M | Sell |
111,025
-600
| -0.5% | -$94.4K | 9.37% | 3 |
|
|
2017
Q3 | $17.4M | Sell |
111,625
-200
| -0.2% | -$31.6K | 8.91% | 2 |
|
|
2017
Q2 | $18.1M | Sell |
111,825
-7,630
| -6% | -$1.24M | 9.86% | 2 |
|
|
2017
Q1 | $18.5M | Sell |
119,455
-1,465
| -1% | -$202K | 10.09% | 2 |
|
|
2016
Q4 | $14.2M | Buy |
120,920
+19,850
| +20% | +$2.27M | 8.46% | 2 |
|
|
2016
Q3 | $11.4M | Sell |
101,070
-2,000
| -2% | -$211K | 8.39% | 2 |
|
|
2016
Q2 | $9.57M | Sell |
103,070
-1,300
| -1% | -$112K | 7.52% | 3 |
|
|
2016
Q1 | $8.17M | Buy |
104,370
+50
| +0% | +$3.6K | 6.54% | 3 |
|
|
2015
Q4 | $7.61M | Sell |
104,320
-680
| -0.6% | -$48.5K | 5.76% | 3 |
|
|
2015
Q3 | $7.8M | Hold |
105,000
| – | – | 6.4% | 3 |
|
|
2015
Q2 | $6.74M | Sell |
105,000
-2,980
| -3% | -$206K | 5.3% | 3 |
|
|
2015
Q1 | $8.34M | Buy |
+107,980
| New | +$8.4M | 6.31% | 2 |
|
Other funds holding IDXX
VCM
VPM
Bourne Lent Asset Management's IDXX Position: Q1 2026 in Review
Bourne Lent Asset Management held its Idexx Laboratories (IDXX) position steady in Q1 2026 at 31,133 shares worth $17.5M. The position accounts for 6.43% of the portfolio, ranked #5.
Bourne Lent Asset Management first reported a position in IDXX in Q1 2015 and has held it in 45 quarters since. The position peaked at $52M in Q4 2021. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Bourne Lent Asset Management held 31,133 shares of Idexx Laboratories worth $17.5M as of Q1 2026.
- Bourne Lent Asset Management left its Idexx Laboratories share count unchanged in Q1 2026.
- Idexx Laboratories made up 6.43% of Bourne Lent Asset Management's portfolio in Q1 2026, its #5 holding.
- Bourne Lent Asset Management first reported a position in Idexx Laboratories in Q1 2015 and has held it in 45 quarters since.
- Bourne Lent Asset Management's Idexx Laboratories position peaked at $52M in Q4 2021.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Bourne Lent Asset Management's 13F filing for Q1 2026, filed 17 Apr 2026.